logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

HER2+ metastatic breast cancer: add-on tucatinib extends survival in HER2CLIMB

Tucatinib was delivered in combination with trastuzumab and capecitabine in heavily pretreated patients.